Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;18(6):e13311.
doi: 10.1111/irv.13311.

Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023-January 2024

Juliette Paireau  1   2 , Cécile Durand  3 , Sylvain Raimbault  4 , Joséphine Cazaubon  1 , Guillaume Mortamet  5 , Delphine Viriot  1 , Christophe Milesi  6 , Elise Daudens-Vaysse  7 , Dominique Ploin  4 , Sabrina Tessier  8 , Noémie Vanel  9 , Jean-Loup Chappert  10 , Karine Levieux  11 , Ronan Ollivier  12 , Jamel Daoudi  13 , Bruno Coignard  1 , Stéphane Leteurtre  14 , Isabelle Parent-du-Châtelet  1 , Sophie Vaux  1
Affiliations

Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023-January 2024

Juliette Paireau et al. Influenza Other Respir Viruses. 2024 Jun.

Abstract

In September 2023, France was one of the first countries that started a national immunisation campaign with nirsevimab, a new monoclonal antibody against respiratory syncytial virus (RSV). Using data from a network of paediatric intensive care units (PICUs), we aimed to estimate nirsevimab effectiveness against severe cases of RSV bronchiolitis in France. We conducted a case-control study based on the test-negative design and included 288 infants reported by 20 PICUs. We estimated nirsevimab effectiveness at 75.9% (48.5-88.7) in the main analysis and 80.6% (61.6-90.3) and 80.4% (61.7-89.9) in two sensitivity analyses. These real-world estimates confirmed the efficacy observed in clinical studies.

Keywords: bronchiolitis; case–control studies; immunisation; monoclonal antibodies; nirsevimab; paediatric intensive care units; respiratory syncytial virus; treatment effectiveness.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Li Y., Wang X., Blau D. M., et al., “Global, Regional, and National Disease Burden Estimates of Acute Lower Respiratory Infections due to Respiratory Syncytial Virus in Children Younger Than 5 Years in 2019: A Systematic Analysis,” Lancet 399, no. 10340 (2022): 2047–2064, 10.1016/S0140-6736(22)00478-0. - DOI - PMC - PubMed
    1. Demont C., Petrica N., Bardoulat I., et al., “Economic and Disease Burden of RSV‐Associated Hospitalizations in Young Children in France, From 2010 Through 2018,” BMC Infectious Diseases 21 (2021): 730, 10.1186/s12879-021-06399-8. - DOI - PMC - PubMed
    1. Meslé M. M. I., Sinnathamby M., Mook P., et al., “Seasonal and Inter‐seasonal RSV Activity in the European Region During the COVID‐19 Pandemic From Autumn 2020 to Summer 2022,” Influenza and Other Respiratory Viruses 17, no. 11 (2023): e13219, 10.1111/irv.13219. - DOI - PMC - PubMed
    1. Vaux S., Viriot D., Forgeot C., et al., “Bronchiolitis Epidemics in France During the SARS‐CoV‐2 Pandemic: The 2020‐2021 and 2021‐2022 Seasons,” Infectious Diseases Now 52, no. 6 (2022): 374–378, 10.1016/j.idnow.2022.06.003. - DOI - PMC - PubMed
    1. Santé publique France , “Bulletin épidémiologique bronchiolite. Bilan de la surveillance 2022–2023,” accessed March 5, 2024, https://www.santepubliquefrance.fr/maladies‐et‐traumatismes/maladies‐et‐....

Publication types

MeSH terms

Substances